**Table S1.** Demographic and clinicopathologic characteristics of three cohorts treated with immune checkpoint inhibitors.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **SKCM ICI (n=174)** |  | **MSK NSCLC ICI (n=240)** |  | **Dana-Farber ICI (n=98)** |
|  | **Van Allen *et al*** | **Snyder *et al***  |  |  |
| **No. of patients** | 110 | 64 |  | 240 |  | 98 |
| **Age** |  |  |  |  |  |  |
| Mean, yrs | 61.0  | 62.0 |  | 66.0 |  | 62.0 |
| Range | 18 – 86 | 18 – 90 |  | 22 – 92 |  | 41 – 79 |
| **Gender** |  |  |  |  |  |  |
| Male | 78 (70.9) | 39 (60.9) |  | 118 (49.2) |  | 55 (56.1) |
| Female | 32 (29.1) | 25 (39.1) |  | 122 (50.8) |  | 43 (43.9) |
| **Smoking** |  |  |  |  |  |  |
| Never | NA | NA |  | 47 (19.6) |  | 19 (19.4) |
| Ever  | NA | NA |  | 193 (80.4) |  | 50 (51.0) |
| Unknown | NA | NA |  | 0 |  | 29 (29.6) |
| **Treatment response** |  |  |  |  |  |  |
| Response | 37 (33.6) | 27 (42.2) |  | 49 (20.4) |  | 34 (34.7) |
| Nonresponse | 73 (66.4) | 37 (57.8) |  | 191 (79.6) |  | 64 (65.3) |
| **Overall survival** |  |  |  |  |  |  |
| Median (95%CI), mo9.0 (1.3-54.4) | 25.6 (2.4-96.1) |  | NA |  | 8.4 (1.1-58.6) |  |
| **Progression-free survival** |  |  |  |  |  |  |
| Median (95%CI), mo | NA | NA |  | 3.2 (0.4-30.5) |  | 4.2 (1.0-32.9) |

Abbreviations: NSCLC, non-small cell lung cancer; SKCM, skin cutaneous melanoma; MSK, Memorial Sloan Kettering; NA, not available; CI, confidence interval, mo, month.